Glenmark Life Sciences Limited (GLS.BO)
INR 1085.8
(0.0%)
INR 1085.8
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.18 Billion INR | -8.13% |
| 2022 | 5.63 Billion INR | 35.34% |
| 2021 | 4.16 Billion INR | -66.51% |
| 2020 | 12.44 Billion INR | -6.01% |
| 2019 | 13.23 Billion INR | -4.57% |
| 2018 | 13.87 Billion INR | 93444.84% |
| 2017 | 14.83 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -23.32 Billion INR | -550.18% |
| 2024 Q2 | 5.46 Billion INR | 123.43% |
| 2023 Q2 | 5.61 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 5.18 Billion INR | -8.13% |
| 2023 Q4 | 5.18 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 5.38 Billion INR | 0.0% |
| 2022 FY | 5.63 Billion INR | 35.34% |
| 2022 Q4 | 5.63 Billion INR | 0.0% |
| 2021 Q2 | 3.51 Billion INR | 0.0% |
| 2021 FY | 4.16 Billion INR | -66.51% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 4.16 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | 0.0% |
| 2020 Q4 | 12.44 Billion INR | -3.32% |
| 2020 Q3 | 12.87 Billion INR | 0.0% |
| 2020 FY | 12.44 Billion INR | -6.01% |
| 2019 FY | 13.23 Billion INR | -4.57% |
| 2018 FY | 13.87 Billion INR | 93444.84% |
| 2017 FY | 14.83 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 68.164% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 96.596% |
| Granules India Limited | 22.95 Billion INR | 77.43% |
| Indoco Remedies Limited | 10.34 Billion INR | 49.906% |
| Achyut Healthcare Limited | 2.01 Million INR | -257272.081% |
| Ajanta Pharma Limited | 10.71 Billion INR | 51.627% |
| Alkem Laboratories Limited | 48.6 Billion INR | 89.341% |
| Alpa Laboratories Limited | 307.12 Million INR | -1586.919% |
| Brooks Laboratories Limited | 248.6 Million INR | -1984.022% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -41.512% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -6.435% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -145.674% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 95.157% |
| Eris Lifesciences Limited | 38.26 Billion INR | 86.462% |
| FDC Limited | 3.7 Billion INR | -39.677% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 92.043% |
| Gufic Biosciences Limited | 5.59 Billion INR | 7.481% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -126.293% |
| Ipca Laboratories Limited | 33.74 Billion INR | 84.646% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1645.822% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -74.211% |
| Lasa Supergenerics Limited | 541.92 Million INR | -856.018% |
| Laurus Labs Limited | 42.71 Billion INR | 87.871% |
| Lupin Limited | 96.23 Billion INR | 94.617% |
| Mankind Pharma Limited | 23.87 Billion INR | 78.3% |
| Medicamen Biotech Limited | 940.36 Million INR | -450.944% |
| Medico Remedies Limited | 438.24 Million INR | -1082.195% |
| Megasoft Limited | 1.85 Billion INR | -179.574% |
| NATCO Pharma Limited | 10.53 Billion INR | 50.808% |
| Piramal Pharma Limited | 74 Billion INR | 92.999% |
| RPG Life Sciences Limited | 1.38 Billion INR | -275.373% |
| Sigachi Industries Limited | 2.53 Billion INR | -104.676% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 97.178% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -154.686% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -344.632% |
| Unichem Laboratories Limited | 8.06 Billion INR | 35.795% |
| Wanbury Limited | 3.15 Billion INR | -64.185% |
| Windlas Biotech Limited | 1.76 Billion INR | -193.918% |
| ZIM Laboratories Limited | 2.08 Billion INR | -148.991% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 92.783% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -33.086% |
| Divi's Laboratories Limited | 18.99 Billion INR | 72.718% |
| Hester Biosciences Limited | 3.59 Billion INR | -44.125% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -102.284% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -560.977% |
| Bal Pharma Limited | 2.51 Billion INR | -106.305% |
| Strides Pharma Science Limited | 37.68 Billion INR | 86.25% |
| Venus Remedies Limited | 1.39 Billion INR | -271.977% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 37.207% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 53.817% |
| Shilpa Medicare Limited | 12.93 Billion INR | 59.939% |
| Aarti Drugs Limited | 11.5 Billion INR | 54.964% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 18.139% |
| Suven Life Sciences Limited | 148.62 Million INR | -3385.981% |
| Ind-Swift Limited | 13.45 Billion INR | 61.489% |
| Valiant Laboratories Limited | 1.05 Billion INR | -389.568% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 51.617% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 63.37% |
| Themis Medicare Limited | 1.88 Billion INR | -174.483% |
| Hikal Limited | 12.99 Billion INR | 60.131% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 93.686% |
| Sequent Scientific Limited | 8.27 Billion INR | 37.385% |
| Novartis India Limited | 1.8 Billion INR | -187.652% |
| Wockhardt Limited | 39.87 Billion INR | 87.006% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 91.545% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1693.947% |
| Neuland Laboratories Limited | 5.49 Billion INR | 5.777% |
| Morepen Laboratories Limited | 4.45 Billion INR | -16.169% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -704.634% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -162.15% |